Research Analysts Issue Forecasts for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Larimar Therapeutics in a research note issued on Monday, June 23rd. Lifesci Capital analyst C. Jubinville expects that the company will earn ($1.84) per share for the year. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

A number of other research firms also recently issued reports on LRMR. HC Wainwright upped their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, March 25th. Robert W. Baird cut their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 25th. Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday. Wedbush cut their target price on shares of Larimar Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Guggenheim restated a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Larimar Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $18.50.

Larimar Therapeutics Stock Down 5.2%

Shares of NASDAQ LRMR opened at $3.08 on Thursday. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $11.20. The company has a market cap of $197.21 million, a price-to-earnings ratio of -2.07 and a beta of 0.79. The firm’s 50-day simple moving average is $2.39 and its 200 day simple moving average is $2.94.

Institutional Trading of Larimar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of LRMR. Monimus Capital Management LP bought a new stake in shares of Larimar Therapeutics in the 4th quarter valued at about $182,000. Fi3 FINANCIAL ADVISORS LLC increased its stake in shares of Larimar Therapeutics by 16.7% in the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock valued at $92,000 after acquiring an additional 3,411 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Larimar Therapeutics by 32.8% in the 4th quarter. American Century Companies Inc. now owns 56,294 shares of the company’s stock valued at $218,000 after acquiring an additional 13,891 shares during the last quarter. AXQ Capital LP bought a new stake in shares of Larimar Therapeutics in the 4th quarter valued at about $91,000. Finally, EntryPoint Capital LLC increased its stake in shares of Larimar Therapeutics by 197.7% in the 4th quarter. EntryPoint Capital LLC now owns 54,281 shares of the company’s stock valued at $210,000 after acquiring an additional 36,045 shares during the last quarter. 91.92% of the stock is owned by institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.